Probability of transplant-free survival at 1 year was over 90% in patients receiving G-CSF versus 57% in those receiving standard medical therapy only.
Alternatives to liver transplantation are needed to treat decompensated cirrhosis. Given recent evidence that granulocyte colony-stimulating factor (G-CSF) might be effective for alcoholic hepatitis, researchers in India evaluated its effect on 12-month transplant-free survival among 65 patients receiving treatment for decompensated cirrhosis at a single tertiary center.
Patients were randomized to standard medical therapy plus G-CSF (1 course every 3 months) plus growth hormone (daily), standard medical therapy plus G-CSF, or standard medical therapy alone for 12 months.
The groups taking G-CSF had significantly lower mortality risk (hazard ratio in group taking growth hormone, 0.16; without growth hormone, 0.09) compared with those receivin…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose